

2014-2015 American Heart Association Support from Pharmaceutical Companies and Device Manufacturers

We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association's finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau's Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations and estates as well as investment earnings and revenue from the sale of educational materials.

Financial support from corporations helps the association's programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association's corporate relations policies, and regional and national corporate relationships are approved by a committee of national volunteers and executive staff.

Total corporate support is comprised of unrestricted gifts and special event and program sponsorships, and includes support committed to the entire American Heart Association, including National Center, its Affiliates and local offices. It represents approximately 20.5 percent of the AHA's \$808,084,882 in total revenue (2014-2015 audited financial statements).

Support that the American Heart Association receives from pharmaceutical companies, device manufacturers and health insurance providers is included within total corporate support and represents approximately 4.4 percent of the association's total revenue. The majority of funding from these sources occurs at the national level.

The revenue figures below include the total amount of funds committed during fiscal year 2014-2015, noting that, in some cases, the funds will be received in future years.



NOTE: The Pie Chart above shows income committed in fiscal year 2014-2015 to the American Heart Association from pharmaceutical companies, device manufacturers and health insurance providers and the amount of total corporate support committed to AHA association-wide, compared to all sources of revenue.

Listed below in the middle column is cash received by the American Heart Association from pharmaceutical companies, device manufacturers and health insurance providers during fiscal year 2014-2015.

In addition, in the right column, we have listed revenue that was committed to the American Heart Association during fiscal year 2014-2015, but will actually be received in future years. An example is a multi-year sponsorship of an American Heart Association program or campaign.

**FY 2014-2015 Contributed Income and Other Revenue Raised at the National Level from
Pharmaceutical Companies and Medical Device Manufacturers**

Corporation	Total Cash Received During FY 2014-2015 on Prior and Current Year Commitments (1)	Current Year FY 2014- 2015 Commitments Receivable in the Future
Abbott Vascular	205,200	52,500
Amgen	2,181,000	666,000
Anthem	0	7,889,886
Arthrex	100,000	-
AstraZeneca	510,000	8,112,500
Bayer Healthcare	200,000	1,293,000
Biotronik, Inc.	60,000	65,000
Blue Cross Blue Shield of SC	-	100,000
Blue Cross Blue Shield of Tennessee	164,500	159,500
BMS/Pfizer	100,000	1,142,000
Boehringer Ingelheim Pharmaceuticals	185,000	25,000
Boston Scientific	50,000	155,000
CardioDX	25,000	-
Chiesi	150,000	-
Cigna	140,000	-
Covidien	1,125,000	-
CPR Working Group	131,250	-
Daiichi Sankyo	650,000	65,000
Edwards Lifesciences LLC	550,000	500,000
Eli Lilly	75,000	-
Genentech	80,000	-
Gilead Sciences	17,500	156,525
Highmark Blue Cross Blue Shield	-	125,000
ISIS Pharmaceuticals, Inc.	2,000	-
Janssen	828,064	175,000
Kaiser Permanente	200,000	150,000
Laerdal Medical Corporation	-	2,415,000
Medpace	-	250,000
Medtronic	1,102,500	750,000
Merck	300,000	100,000
Novartis Pharmaceuticals	2,604,152	4,220,000
Pfizer	75,000	10,000
Philips Healthcare	528,500	315,000
Physio-Control	12,500	-
Regeneron	5,000	-
Roche Diagnostics	10,000	-
Sanofi	325,000	195,000
Siemens	75,000	-
Stryker Neurovascular	-	15,000
Takeda Pharmaceutical Company Limited	803,990	-
Zoll Medical	15,000	-
Zontivity	-	20,000
Totals	13,586,156	29,121,911

Note: (1) Reflects all corporate contributions to National Center and 10 highest corporate contributions to each Affiliate.

Note (2) Column includes cash received on commitments from contracts and conferences. This was recorded as revenue in FY 2011-12, FY 2012-13, FY 2013-14, FY 2014-15.